# Experimental Therapeutics of Cancer Scientific Program

> **NIH NIH P30** · UT SOUTHWESTERN MEDICAL CENTER · 2020 · $45,512

## Abstract

Harold C. Simmons Cancer Center 
Experimental Therapeutics of Cancer Scientific Program 
Project Summary/Abstract 
The Experimental Therapeutics (ET) Program brings together 44 full Simmons Cancer Center (SCC) 
members, including 13 from basic science departments and 31 from clinical departments, to develop novel 
therapeutic strategies and to evaluate these approaches by conducting investigator-initiated clinical trials. The 
program has 27 NCI projects, a lung cancer SPORE, as well as 12 multi-investigator awards. ET Program 
clinical investigators represent key oncology disciplines, including medical, surgical, pediatrics, and radiation 
oncology; radiology; and pathology. Investigators in the ET Program are currently supported by over $24.7 
million in peer-reviewed funding (total costs) with $7.5 million from the NCI, $4 million from other NIH sources, 
and $7.3 million from the Cancer Prevention and Research Institute of Texas (CPRIT) 
The ET Program is designed to provide an organized, science-based conduit for translating SCC discoveries 
from the scientific programs to the clinic, and to help establish appropriate preclinical models and data to 
facilitate clinical translation. Likewise, clinical data are then used to form new hypotheses tested by our strong 
basic science foundation throughout the SCC. The program themes focus on drug (Themes 1,2) and 
biomarker (Themes 3,4) discovery to identify optimal populations for these new treatments. 
· Theme 1: Molecular Therapeutic Sensitizers 
· Theme 2: Tumor Microenvironment and Protein Therapy 
· Theme 3: Imaging and Drug Delivery 
· Theme 4: Cancer Vulnerabilities 
The Co-Leaders of the ET Program work together to foster and develop themes, goals, membership, and new 
collaborations in specific research areas for clinical translation. This process heavily engages SCC disease 
DOTs (disease oriented teams) to focus specific therapeutics on select cancers, as evidenced by mechanistic- 
based research where target validation is assessed using pharmacodynamic biomarkers. These activities, in 
turn, stimulate intra- and inter-programmatic collaborations. The ET Program averages over 100 publications 
per year, and since 2009 the level of collaborative publications has remained quite high, with 35% intra- 
programmatic, 34% inter-programmatic and 28% inter-institutional with authors in other NCI-designated cancer 
centers.

## Key facts

- **NIH application ID:** 10260733
- **Project number:** 3P30CA142543-10S3
- **Recipient organization:** UT SOUTHWESTERN MEDICAL CENTER
- **Principal Investigator:** Carlos L Arteaga
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $45,512
- **Award type:** 3
- **Project period:** 2010-08-03 → 2021-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10260733

## Citation

> US National Institutes of Health, RePORTER application 10260733, Experimental Therapeutics of Cancer Scientific Program (3P30CA142543-10S3). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10260733. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*